It also reduces gastrointestinal motility, aiding in the stabilization of blood glucose levels in type 2 diabetes after therapy with exogenous GLP-1, and enhances satiety, with a consequent reduction in food intake [52]. This evidence concerns the gene GCG and type 2 diabetes mellitus.